Healthy Clinical Trial
Official title:
Efficacy of Movement Breaks in Real-World Settings
Verified date | December 2023 |
Source | University of British Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy of performing "exercise snacks" (short movement breaks throughout the day) on various measures of cardiometabolic health.
Status | Completed |
Enrollment | 77 |
Est. completion date | December 5, 2023 |
Est. primary completion date | December 5, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 64 Years |
Eligibility | Inclusion Criteria: 1. Physically inactive (performing <150 minutes of moderate-to-vigorous intensity aerobic exercise per week, assessed by pre-screening Get Active Questionnaire); 2. Body Mass Index: 18.5-30.0 kg/m2; 3. Not currently diagnosed with or being treated for cardiometabolic disease (e.g., coronary artery disease, diabetes); 4. Not a current smoker; 5. Cleared to engage in physical activity using the Get Active Questionnaire and, if applicable, consultation with a Qualified Exercise Professional; 6. Access to a computer, tablet or smartphone for intervention delivery and tracking Exclusion Criteria: 1. Chronic health condition preventing participation in exercise; 2. Lack of access to internet connection |
Country | Name | City | State |
---|---|---|---|
Canada | McMaster University | Hamilton | Ontario |
Canada | University of British Columbia | Kelowna | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Canadian Cancer Society (CCS), Canadian Institutes of Health Research (CIHR), McMaster University |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline in Cardiorespiratory Fitness at 12 Weeks | Cardiorespiratory fitness will be assessed as the highest 30-s average from a laboratory-based graded VO2peak test on a cycle ergometer. | Baseline and Week 12 | |
Secondary | Change from Baseline in Plasma Insulin | A fasted venous blood sample will be obtained and insulin measured by commercial assay. | Baseline and 12 weeks | |
Secondary | Change from Baseline in Plasma Glucose | A fasted venous blood sample will be obtained and glucose measured by biochemical assay. | Baseline and 12 weeks | |
Secondary | Change from Baseline in Insulin Resistance | A fasted venous blood sample will be obtained and insulin resistance estimated by homeostasis model assessment (HOMA) score | Baseline and 12 weeks | |
Secondary | Change from Baseline in Inflammatory cytokines | A fasted venous blood sample will be obtained and inflammatory cytokines measured by multiplex assay | Baseline and 12 weeks | |
Secondary | Change from Baseline in Body Mass | Body mass will be measured by weigh scale | Baseline and 12 weeks | |
Secondary | Change from Baseline in Waist Circumference | Waist circumference (in centimetres) will be measured using a measurement tape. | Baseline and 12 weeks | |
Secondary | Device-Measured Adherence to Movement Breaks | Participants will wear accelerometers to assess adherence near the beginning and the end of the intervention. | Week 2 and week 11 | |
Secondary | Self-Reported Adherence to Movement Breaks | Participants will be sent weekly surveys asking them to recall the total number of movement breaks performed that week. | Once per week for 12 weeks | |
Secondary | Movement Break Enjoyment assessed by the Exercise Enjoyment Scale (EES) | The EES is a validated, single-item 7-point scale to assess exercise enjoyment. Possible scores range from 1 (not at all) to 7 (extremely). | Immediately following each movement break for entire 12-week intervention | |
Secondary | Rating of Perceived Exertion (RPE) following Movement Breaks | A 10 point RPE scale will be used to assess perceived exertion ranging from 0 (rest) to 10 (maximal). | Immediately following each movement break for entire 12-week intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |